TransCode Therapeutics (NASDAQ: RNAZ) has announced significant advancements in its global intellectual property portfolio, securing patent protections in Australia and Japan for its RNA-based cancer therapies. These developments underscore the company's strategic focus on protecting its innovative nanoparticle delivery platforms and RNA therapeutics, which could play a crucial role in the future of cancer treatment.
In Australia, IP Australia has accepted Patent Application No. 2019349817, covering therapeutic nanoparticle compositions designed to deliver small interfering RNA (siRNA) molecules for cancer treatment. The allowed claims encompass nanoparticle compositions and methods of use across multiple cancer types, including colon, lung, breast, pancreatic, and ovarian cancers. The patent is expected to proceed to grant with a projected expiration date of September 6, 2039. This acceptance not only validates TransCode's technology but also provides a long-term exclusivity window in a key market, potentially attracting partnerships and investment.
Simultaneously, the Japan Patent Office (JPO) issued a Notice of Allowance, followed by the grant and issuance of Japanese Patent No. 7886877. This patent covers RNA-based immunomodulatory compositions designed to selectively activate innate immune pathways within tumors and the tumor microenvironment. The claims include compositions targeting cancers expressing miR-21 and nanoparticle-enabled delivery approaches incorporating magnetic or polymer-coated systems. This patent strengthens TransCode's position in Japan, a major pharmaceutical market, and highlights the versatility of its technology across different RNA mechanisms.
These patent achievements are critical for TransCode Therapeutics as they provide a foundation for commercializing its pipeline. The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. With additional first-in-class candidates aimed at mobilizing the immune system, the expanded patent estate could accelerate clinical development and enhance the company's ability to secure funding and collaborations. For investors, these milestones signal progress in building a robust IP moat, which is essential in the competitive oncology landscape.
To view the full press release, visit https://ibn.fm/Pqy4e. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
About InvestorWire: InvestorWire is a specialized communications platform with a focus on advanced wire-grade press release syndication. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
